Task-Fit Over Benchmark Score: A Model Selection Framework for Clinical AI Deployments

Healthcare AI procurement is converging on a repeatable mistake. Technical leaders evaluate frontier models against general capability benchmarks, select the highest-scoring option, and then discover in production that benchmark performance and clinical task accuracy are measuring different things. The gap is not a calibration problem that disappears with more data or a longer evaluation window. It is structural, and it follows directly from the mismatch between how general-purpose models are trained and what clinical tasks actually require.

Companion piece to our broader work on clinical AI validation. See AI Diagnostic Models in Healthcare: Hidden Validity Failures for how validation failures propagate from training assumptions into production systems.

Why General Benchmarks Diverge from Clinical Task Performance

General capability benchmarks measure breadth. They test a model's ability to perform competently across a wide range of language, reasoning, and perception tasks drawn from general-domain distributions. Clinical tasks are narrow, precise, and often defined by failure modes that never appear in those distributions.

A model that scores well on general medical question-answering benchmarks has demonstrated that it can retrieve and reason over biomedical text at a population level. It has not demonstrated that it can measure left ventricular internal diameter to within two millimetres, or that its output is stable across the imaging variation present in a specific hospital's ultrasound fleet. These are different competencies, and conflating them is how procurement errors happen.

The numerical precision problem is a concrete illustration of this divergence. Standard vision-language models represent numbers as discrete tokens, which means that a measurement of 12.3 mm and a measurement of 12.8 mm are as far apart in the model's representation space as 12.3 mm and 87.1 mm. Huang et al. (arXiv 2026) demonstrate that this tokenisation artefact produces systematic measurement errors in echocardiographic tasks, and that replacing discrete numerical prediction with a diffusion-based continuous prediction head reduces mean absolute error by 21 to 37 percent across four cardiac measurement tasks. The architecture fix is real, but the more important point for procurement is that no general benchmark would have surfaced this failure before deployment.

The Case for Narrow Fine-Tuning Over Frontier Model Access

The default assumption among enterprise buyers is that a more capable frontier model is a safer choice. The reasoning is intuitive: if the model is better at everything, it should be better at the clinical task too. This assumption fails in domains where the task requires a capability that frontier training does not specifically develop.

Narrow fine-tuning on task-specific data consistently outperforms general-purpose frontier models on well-defined clinical tasks, provided the fine-tuning data is representative of the deployment distribution. The mechanism is straightforward: fine-tuning shifts the model's parameter space toward the specific input-output mapping the clinical task requires, rather than averaging across thousands of unrelated tasks that dilute that signal.

The cost implication follows directly. Frontier model API access at diagnostic workload volumes carries inference costs that compound at scale. A fine-tuned smaller model running on dedicated infrastructure will typically deliver lower latency, lower per-inference cost, and better task-specific accuracy simultaneously. The tradeoff is upfront investment in fine-tuning and validation, which is recoverable across the deployment lifecycle.

Latency and Cost Considerations for Diagnostic Workloads

Clinical AI systems have latency requirements that differ from general enterprise AI. A model supporting real-time imaging guidance needs to return a result within the procedural window. A model supporting triage needs to process a queue without creating a bottleneck that delays clinical decision-making.

Frontier model API calls introduce network latency that is non-deterministic and dependent on provider infrastructure. For asynchronous reporting tasks, this may be acceptable. For real-time or near-real-time clinical applications, it is a deployment constraint that needs to be resolved at the architecture selection stage, not after go-live.

Cost modelling for diagnostic workloads should be built on realistic volume projections with a clear unit economics calculation. The comparison should be between frontier API access at projected volume versus fine-tuned model infrastructure cost amortised over the deployment period. Teams that skip this calculation frequently find that the frontier model option is economically unsustainable at clinical scale.

Structuring Internal Validation Before Committing to a Model Architecture

In a regulated environment, the validation process is not a final checkpoint. It is a design input. The validation strategy should be defined before model selection is finalised, because the choice of validation methodology constrains which model architectures are viable.

Internal validation for clinical AI needs to address three distinct questions that general enterprise AI evaluation does not. First, does the model perform acceptably across the patient subgroups present in the deployment population, not just in aggregate? Second, is performance stable across the imaging or signal variation introduced by the specific hardware in the deployment environment? Third, does the model's failure mode produce outputs that are clinically interpretable, so that a clinician can identify when the model is wrong?

Each of these questions requires a held-out test set constructed with those questions in mind. A test set assembled from the same distribution as the training data will not surface subgroup failures. A test set collected on a single device will not surface hardware variation effects. Defining the test set structure before model selection forces the evaluation to measure what clinical deployment actually requires.

A Practical Selection Process for Clinical Contexts

The selection process that follows from this analysis has a different sequence than standard enterprise AI evaluation. It starts with task specification before any model is evaluated, defines the validation protocol before any model is selected, and treats benchmark scores as a filter for initial shortlisting rather than a selection criterion.

The practical steps are:

1. Define the clinical task in precise input-output terms, including acceptable error bounds and failure mode tolerances.
2. Construct a representative evaluation dataset from the deployment population and hardware environment.
3. Apply the validation protocol to each shortlisted model, including subgroup analysis and hardware variation testing.
4. Model the unit economics of each architecture option at realistic deployment volume.
5. Select the architecture that meets the clinical performance threshold at acceptable cost, not the architecture with the highest general benchmark score.

This process is more expensive upfront than selecting a frontier model and beginning integration. It is substantially less expensive than discovering a systematic failure in production in a regulated environment where remediation requires a regulatory change notification and a new clinical evaluation.